In 1984, the first prognostic indicator for advanced non-Hodkin's lymphoma was developed. An information theory guided, computer search and evaluation procedure entropy minimax was employed to discover the largest sub-groupings for which survival is as extreme as possible Patterns of survival in advanced non-Hodgkin's lymphoma. International Conference on Malignant Lymphoma; June 13-16, 1984; Lugano, Switzerland; Proceedings: "Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances:: F. Cavalli, G. Bonadonna, M. Rozencweig, Martinus Nijhoff Publ.; Springer.com/book/10.1007/978-1-4613-2607-6, date=1985 In the clinical trials analyzed retrospectively and containing a large fraction of patients not matching the 'good' - of 'good'  , 'poor'  and 'intermediate'  prognosis patterns identified, a significant difference was found between the survival of patients with and those without a complete response to therapy. The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference.
In 1984, the first prognostic indicator for advanced non-Hodkin's lymphoma was developed. An information theory guided, computer search and evaluation procedure entropy minimax was employed to discover the largest sub-groupings for which survival is as extreme as possible Patterns of survival in advanced non-Hodgkin's lymphoma. International Conference on Malignant Lymphoma; June 13-16, 1984; Lugano, Switzerland; Proceedings: "Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances:: F. Cavalli, G. Bonadonna, M. Rozencweig, Martinus Nijhoff Publ.; Springer.com/book/10.1007/978-1-4613-2607-6, date=1985 In the clinical trials analyzed retrospectively and containing a large fraction of patients not matching the 'good' - of 'good' (Karnofsky status >_80 and 'A" Symptoms and SGOT <36 U/L) , 'poor' (Karnofsky status <70 or Night sweats) and 'intermediate' (All remaining) prognosis patterns identified, a significant difference was found between the survival of patients with and those without a complete response to therapy. The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference.
A
(Karnofsky status >_80 and 'A" Symptoms and SGOT <36 U/L)
A
(Karnofsky status <70 or Night sweats)
A
(All remaining)